atepeq/tico19 huggingface dataset:
Pregnant women may be at higher risk for severe infection with COVID-19 based on data from other similar viruses, like SARS and MERS, but data for COVID-19 is lacking.In some people, COVID-19 may affect the lungs causing pneumonia.
Kǝshana surowade waniye sandima alamaram taidazǝ COVID-19 zamjinnofutǝ kulashi kasuwa gaden safsanadǝn fulzǝnadǝbe turunalana alamanna SARS so MERS beson. Am lasodǝ COVID-19 zamjiya waniye fufuna lezǝ kasuwa nimoniyabero waljin.
In those most severely affected, COVID-19 may rapidly progress to acute respiratory distress syndrome (ARDS) causing respiratory failure, septic shock or multi-organ failure.
Am la taidazǝ COVID-19 zamzǝnadǝ kasuwa ganjibero waljin adǝbe sǝkǝ fufunza cidajin baro waljin.
Complications associated with COVID-19 include sepsis, abnormal clotting and damage to the heart, kidneys and liver.
Awo a kaziyi COVID-19 bega kǝllatadǝ sandima sepsis a clottinga banna karuwa Kǝndǝliramma Kǝmatǝnaro sǝdin.
Clotting abnormalities, specifically an increase in prothrombin time, have been described in 6% of those admitted to hospital with COVID-19, while abnormal kidney function is seen in 4% of this group.
Cidaga kalkalo gǝnyi Clotting kǝndodǝ, hasatan nzǝra loktǝ prothrombin sǝdin , kuru sana6% am litarin rozana COVID-19, bedǝ Kǝndǝliramza kalkallo cidazainba.
Approximately 20-30% of people who present with COVID-19 demonstrate elevated liver enzymes (transaminases).
Ta'adir sana 20-30% sadǝnama am ndonyi kǝrmamaro COVID-19 kaziy kǝmattǝnbega.
According to the same report, the median time between onset of symptoms and death was ten days, with five being spent hospitalised.
Futǝ hawardǝbe bayanzǝnaladǝn lamkate loktǝbeladǝn alamaram a kǝrmu begadǝ kawu 10 kuru 5 litari itagatsain.
However, patients transferred to an ICU had a median time of seven days between hospitalisation and death.
kuruson yayi kam dondido dalamu kam zauro dondiga rotinro kalktǝya kawu 7 lamkate sha litarin rota kǝmu abedǝn daga.
In a study of early cases, the median time from exhibiting initial symptoms to death was 14 days, with a full range of six to 41 days.
Kulashi datebeladǝn fulezǝna alamaram badiyarambega kǝrmubegadǝ kawu 14 rakt3 kamil 6 gozǝ kawu 41 sadǝnaldǝn kara.
In a study by the National Health Commission (NHC) of China, men had a death rate of 2.8% while women had a death rate of 1.7%.
Kulashi huwuma nalewabe NHC lardǝ Chinabe dǝye wono adadu kǝrmu Kongabedǝ sana 2.8% Kamuwabedǝ sana 1.7%.
Histopathological examinations of post-mortem lung samples show diffuse alveolar damage with cellular fibromyxoid exudates in both lungs.
Jaraf Histopathologicalbe dǝbe ngawo awo shiro post-mortem fufube dǝga tǝdǝnalan misal turuna alveolarga bannazǝnbe adǝyeyima fibromyxoid exudates fufube samma bannazǝnaro tawattǝna.
Viral cytopathic changes were observed in the pneumocytes.
faltǝ Viral cytopathic dǝga pneumocyteslan fodǝtǝna.
The lung picture resembled acute respiratory distress syndrome (ARDS).
Foto fufubedǝ samunga kasuwa ganjibe shiro ARDS gulzailadǝn.
In 11.8% of the deaths reported by the National Health Commission of China, heart damage was noted by elevated levels of troponin or cardiac arrest.
sana 11.8% be hawar huwuma Nalewabe lardǝ Chinabe sǝtulunadǝn karuwuwa am dǝyedǝ bannatǝna kuru shidǝ tǝra troponin au Cardiacro waltǝlan.
According to March data from the United States, 89% of those hospitalised had preexisting conditions.Availability of medical resources and the socioeconomics of a region may also affect mortality.
Kulashi kǝntau March be lardǝ United State sǝdǝnadǝ 89% am litarin rozanadǝ hallan kasheru. Karewa litabe samma tǝngǝrro sandiya sǝnasolan amma lamarra arziyibe dalamudǝbedǝ shiye bana kǝrmudǝro sǝdǝna.
Estimates of the mortality from the condition vary because of those regional differences, but also because of methodological difficulties.
Adadu kǝrmubedǝ gade-gade dalamu gade-gaden mondu gadegaden tǝwando kaziyi adǝga sǝwudǝ.
The under-counting of mild cases can cause the mortality rate to be overestimated.
Kongomi tǝdinladǝn kasuwa ganaganadǝ shima dalilo kǝrmo kada sǝwudǝna konkomima kozǝna.
However, the fact that deaths are the result of cases contracted in the past can mean the current mortality rate is underestimated.
Ndasoson yayi shaida kǝrmube dalil kasuwabe gozǝna a kǝrmabedǝ somtinbawo.
Smokers were 1.4 times more likely to have severe symptoms of COVID-19 and approximately 2.4 times more likely to require intensive care or die compared to non-smokers.Concerns have been raised about long-term sequelae of the disease.
Tafa kǝzamadǝ loktǝ 1.4 alamaram kasuwa COVID-19 na kojibe sǝtayin kuru loktǝ 2.4 sandima muradǝ gananaram kam zuro dondiben gǝnatin susu am tafa sasainbawo lan.
The Hong Kong Hospital Authority found a drop of 20% to 30% in lung capacity in some people who recovered from the disease, and lung scans suggested organ damage.
Huwuma litabe Hong Kong ben ngawo wuzǝnaro tǝwandǝna alamanna sana 20% - 30% kasuwa fufubelan gatǝlan kuru injin scan be dǝye shaworiga cina dalami bannatǝnaso la dǝn.
This may also lead to post-intensive care syndrome following recovery.
Adǝ shima sǝdǝ fasal ngawo gǝnanaram kam dondi zaubedǝga gotǝga sǝwudin gawo alamaramdǝn gatǝnaben.
As of March 2020, it was unknown if past infection provides effective and long-term immunity in people who recover from the disease.
Kǝntau March be sa'a 2020 beladǝn am notǝnyi zamzǝna dǝga sandiro awo ndǝne tiyibe loktǝ kuruwuro idajinma am kasuwadǝn ngazanaro kǝndolan.
Immunity is seen as likely, based on the behaviour of other coronaviruses, but cases in which recovery from COVID-19 have been followed by positive tests for coronavirus at a later date have been reported.
Tiyiye dunodǝ alamaram sha turindǝ, hallan gotin coronavirusso kuru hal ngatǝwa COVID-19 tǝwandobega kuru ngawo jaraftǝ coronavirus be tǝdǝ nadin mbeji fulezǝnaben hawar dǝga gattǝga.
These cases are believed to be worsening of a lingering infection rather than re-infection.
Hal adǝbeladǝn tǝma mbeji hal dǝga zauzǝna futǝ kasuwayedǝma kozǝnaro.
The virus is thought to be natural and have an animal origin, through spillover infection.
Kuli kasuwabedǝ Alamen kadiwo kuru gargamzǝ dabbalan tǝwando.
The actual origin is unknown, but by December 2019 the spread of infection was almost entirely driven by human-to-human transmission.
Gargam nzǝ hayyabedǝ notǝnyi, amma kǝntau December be 2019 ladǝn kasuwa tartǝga ndarasoro badiwono kuru kamlan cizǝ kamro kojin.
A study of the first 41 cases of confirmed COVID-19, published in January 2020 in The Lancet, revealed the earliest date of onset of symptoms as 1 December 2019.
Kulashi tǝdǝna kǝn auwalbe am 41 COVID-19 sǝtana tawattǝna kǝntau January be sa'a 2020 ladǝn Lancet be lufsnaldǝn bayanzǝna almaram nzǝ kǝndau December 1-2019 beladǝn.
Official publications from the WHO reported the earliest onset of symptoms as 8 December 2019.
Luftǝ maila Huwuma WHO lufsǝnaladǝn alamaram faldǝ kǝndau December be kau nzǝ 8-2019 tawattkatǝ.
Several measures are commonly used to quantify mortality.
Kataf kada gotǝna tajirwa robega kaltǝro.
These numbers vary by region and over time and are influenced by the volume of testing, healthcare system quality, treatment options, time since initial outbreak and population characteristics such as age, sex and overall health.
Adadǝ adǝ nǝmgade dalamiyeso loktǝbeso kulashibeso nalewa ngalauso kataf kurun kǝndobeso fulentǝso nǝmngǝwu halbeso sa'ayeso kamuso Kwabeso nalewa samma begaso.
In late 2019, WHO assigned the emergency ICD-10 disease codes U07.1 for deaths from lab-confirmed SARS-CoV-2 infection and U07.2 for deaths from clinically or epidemiologically diagnosed COVID-19 without lab-confirmed SARS-CoV-2 infection.The death-to-case ratio reflects the number of deaths divided by the number of diagnosed cases within a given time interval.
Dareram sa'a 2019 WHO dalami duwasashibe ICD-10 kasuaw be lamba shilan faidatǝbe Nasarlan shiro code gulzaindǝg kaino sandima UO7.1 kǝrmu njim kulashiben tawattǝnaro SARS-CoV-2 a U07.2 kǝrmu litari kasuwa kaltǝbe COVID-19 tawatǝnyi. Kǝrmua adǝ adudǝnzabe fǝlzǝna sǝro loktǝga laben.
Based on Johns Hopkins University statistics, the global death-to-case ratio is 6.9% (153,822/2,240,191) as of 17 April 2020.
Futǝ Jamiya Johns Hopkins konkominzǝdǝn, adadu kǝrmu Dunyabeladǝn sana 6.9% (153,822/2,240,191) katau April 17 -2020 tǝwandǝ.
The number varies by region.Other measures include the case fatality rate (CFR), which reflects the percent of diagnosed individuals who die from a disease, and the infection fatality rate (IFR), which reflects the percent of infected individuals (diagnosed and undiagnosed) who die from a disease.
Adadudǝ dalamilabe laga kozǝna. Kataffa la gotǝnamasodǝbe sǝron loru fǝlutǝso lamkate am kasuwabe zamzǝnabeladǝn adǝbe adadunzaga flujin kǝrmuwa kasuwason.
These statistics are not time bound and follow a specific population from infection through case resolution.
Konkomi adǝ loktǝnzǝ datǝbe bawo kuru adadu taganasbe am kasuwabe zamzǝnabe tawatǝ shiro datǝnaba.
While not all infected people develop antibodies, the presence of antibodies may provide information about how many people have been infected.
A'a am zamzǝna samma gǝnyi awo tiyibe wazǝna alamanna nǝm kanjuwa sanadin, alamaram nǝm kanjubedǝ hawar am dawu zamzǝbe shilan tǝwandin.
In the epicentre of the outbreak in Italy, Castiglione d'Adda, a small village of 4600, 80 (1.7%) are already dead.
Dawudi donyi wawa dǝ fulenzǝna lardǝ Italy, Castiglione d'Adda, Buladiya adadunzǝ kam 4600, 80 a sana (1.7%) ba bazana.
In Gangelt, the disease was spread by Carnival festivals, and spread to younger people, causing a relatively lower mortality, and not all COVID-19 deaths may have been formally classified as such.
Gangeltǝ lan, kasuwadǝ loktǝ kǝlele sa'abe tartǝ citǝbulinmiso a cita, amma kǝrmu gana amma samma kǝrmu COVID-19 begǝnyi amma waniye adǝgairo yeyeksanyi.
Furthermore, the German health system has not been overwhelmed.
kurusolan cidara litabe lardǝ German be dǝ futǝmatindǝro tǝdǝnyi.
In the Netherlands, about 3% may have antibodies, as assessed from blood donors.
Lardǝ Netherlands belan awo tiyiye wazǝnadǝ waniye sana 3% lezǝna adǝga loktǝ bana bube kǝndoben fodǝwotǝ.
69 (0.004% of the population) have been confirmed to have died from COVID-19.
adadu sana 69 (0.004%) am adǝ kasuwa COVID-19 loruzǝro tawattǝna.
The impact of the pandemic and its mortality rate are different for men and women.
Loru wawabe lamkatǝ kamuwa Kwangawadǝ gade.
Mortality is higher in men in studies conducted in China and Italy.
Kulashi kǝla loru kongbeladǝn lardǝ China Italiaben tǝdǝnadǝn kongama nguwuro lorujinno tawattǝna.
The highest risk for men is in their 50s, with the gap between men and women closing only at 90.
Tajirwa kongalan nguwunzaso sa'a 50 lan baditin, lamkte kamuwa kongabedǝ sana 90 lezǝna.
In China, the death rate was 2.8 percent for men and 1.7 percent for women.
Lardǝ China ben adadu kǝrmubedǝ sandima kongabe sana 2.8% Kamuwabe sana 1.7%.
The exact reasons for this sex-difference is not known, but genetic and behavioural factors could be a reason.
Tawadǝ nǝmgde kamuwa Kwabedǝ notǝnyi, amma nǝmbiya kurkuri adǝga halladǝ shima dalilworo waljin.
Sex-based immunological differences, lesser prevalence of smoking in women and men developing co-morbid conditions such as hypertension at a younger age than women could have contributed to the higher mortality in men.
Nǝmgade kamuwa kwabedǝ tawa kǝnza gana kamuwabe kuru Kongadǝ sandi hal gade-gade alamanna sa sandi citǝbulinmidǝn hankalcinoso dǝ shima banazǝ sandiyalorujin.
In Europe, 57% of the infected individuals were men and 72% of those died with COVID-19 were men.
Lardǝga Europe beladǝn sana 57% am zamzǝnadǝ Konga kuru sana 72% am COVID-19 loruzǝnadǝbe Konga.
As of April 2020, the US government is not tracking sex-related data of COVID-19 infections.
Kǝntau April 2020 Gomnati lardǝ U.S adadu am COVID-19 zamzǝnadǝ nǝmgade kamuso kwabesoga safsǝnyi.
Research has shown that viral illnesses like Ebola, HIV, influenza and SARS affect men and women differently.
Kulashibe futǝ fulezǝnaladǝn kasuwa Ebolaso HIVso Tantayiso SARSso samma kwa a kamuwa samma zamzain nǝmgade baro.
A higher percentage of health workers, particularly nurses, are women, and they have a higher chance of being exposed to the virus.
Kambo cidawu litabedǝ Kǝshana hasatanma cidawu rewi kuru alamaram sandima Kuli kasuwabe zamcinye mbeji.
The World Health Organization announced on 11 February 2020 that the official name of the disease would be "COVID-19".
Huwuma Nalewa Dunyabe WHO yim kawu kǝntawube 11 February 2020 su kasuwadǝbe mailaro sha COVID-19 lan bowono.
WHO chief Tedros Adhanom Ghebreyesus explained that CO stands for corona, VI for virus, D for disease, and 19 for when the outbreak was first identified: 31 December 2019.
Huwuma WHO beye cidamanzǝ chief Tedros Adhanom Ghebreyesus bayanzǝladǝn wono CO dǝ corona, VI dǝ virus, D dǝ Kasuwa, kuru 19 loktǝ fulenzǝnawo: 31 December 2019.
The name had been chosen to avoid references to a specific geographical location (e.g. China), animal species or group of people, in line with international recommendations for naming aimed at preventing stigmatisation.The virus that causes COVID-19 is named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Su dǝga kartǝ gowotǝ wande dalamulan mislatǝnyi alamanna China, Dabba, kufu jamabe diwal shawori lardǝga-lardǝwaben kurunya sudǝbedǝ njutǝga kaltǝ. Kulidǝbe su COVID-19 kaziyi yintǝbe danoye alamaram dǝ shima coronavirus 2 (SARS-CoV-2) dǝwo.
The WHO additionally uses "the COVID-19 virus" and "the virus responsible for COVID-19" in public communications.
Huwuma WHO beye sǝra faidagatǝ "kuli COVID-19 belan" kulidǝ shima dalil COVID-19 sǝro muamala jamaben faidatǝlan.
Both the disease and virus are commonly referred to as "coronavirus".
Kasuwa dǝga kuli dǝgasoro coronavirus ada.
During the initial outbreak in Wuhan, China, the virus and disease were commonly referred to as "coronavirus" and "Wuhan coronavirus".
Loktǝ fulenzǝna kaldǝn sǝro bula Wuhan lardǝ China bedǝn kuli kasuwa bedǝga "coronavirus" gada kuruson "Wahan coronavirus" yesana.
In January 2020, WHO recommended 2019-nCov and 2019-nCoV acute respiratory disease as interim names for the virus and disease in accordance with 2015 guidance against using locations in disease and virus names.
Kǝntau January 2020 ladǝn huwuma WHO be kasadsǝ 2019-nCov a 2019-nCoV su kuli dǝga kasuwadǝgabero gowono futǝ kasuwa yintǝbe sa 2015 diwal faidata su kasuwadǝga kuli dǝgaro sakǝ dalamun fadatayibedǝn gaweta codo.
The official names COVID-19 and SARS-CoV-2 were issued on 11 February 2020.
Su maila COVID-19 a SARS-CoV-2 kǝntau February 11-2020 satǝluwo.
Due to capacity limitations in the standard supply chains, some digital manufacturers are printing healthcare material such as nasal swabs and ventilator parts.
Dalia mbatǝga nǝmgalau diwal taga kareaw nalewabe zaman bega kǝndobe alamanna Nasal swabs beso dalami kasambeso kudon.
In one example, when an Italian hospital urgently required a ventilator valve, and the supplier was unable to deliver in the timescale required, a local startup reverse-engineered and printed the required 100 valves overnight.
Misalla fallan loktǝ Italianbe litarinzǝbe duwasashi ventilator valve be muradǝzǝnaladǝn loktǝ muradǝzǝnaladǝn sǝwandǝnyi illa mundǝma sǝro fatobelan gaweta vaves 100 muradǝtǝna dǝga bune fal baksa wawono.
After the initial outbreak of COVID-19, conspiracy theories, misinformation and disinformation emerged regarding the origin, scale, prevention, treatment and other aspects of the disease and rapidly spread online.
Loktǝ COVID-19 fulenzna kaldǝ kawuli bastǝbeso manafaudǝbeso gafsǝnazǝga badiyetǝ kǝla gargamzǝben a kaltǝga kurunzǝga kǝla kasuwadǝben kuru futǝ duwa-dǝwaro nduwu Dunya ndǝftǝben tartǝzǝgaben.
Humans appear to be capable of spreading the virus to some other animals.
Adam gana dǝ shima raksǝ kuli dǝga dabba tarjinwo.
The study failed to find evidence of viral replication in pigs, ducks, and chickens.
Kulashi dǝbe shaida kuli dǝga Goduso, Agwagwaso Kuyinso lan tǝwandosana dǝbe kǝlan sǝwadǝ nyi.
No medications or vaccine is approved to treat the disease.
Kurun au kalimi kǝla kasuwa dǝben tawattǝna bawo.
International research on vaccines and medicines in COVID-19 are underway by government organisations, academic groups and industry researchers.
Kulashi kurunna kalimi COVID-19 dǝ kǝla diwalben kara huwuma Gomnatibe a kufu Mallumma bega kulashiwo sanyarambega sammalan kǝndolan kasheru.
In March, the World Health Organization initiated the "SOLIDARITY Trial" to assess treatment effects of four existing antiviral compounds with the most promise of efficacy.
Kǝntau March, bela huwuma World Health Organization ye dawori kǝla kǝlbe sha "SOLIDARITY Trial"notǝnama dǝga sǝdǝ faida kurunbe 4 sasǝrzǝ wadǝ kambolan gatsǝna.
There is no available vaccine, but various agencies are actively developing vaccine candidates.
Kalimi kamil ba amma huwuma kada tarai ciza dazana kalimiga sadin na kasheru.
Previous work on SARS-CoV is being utilised because SARS-CoV and SARS-CoV-2 both use the ACE2 receptor to enter human cells.
Cida burome kǝla SARS-Cov bedǝ faidatǝna dalil SARS-CoV a SARS-CoV-2 samma ACE2 lan faidatana tiyi Adam ganaben.
There are three vaccination strategies being investigated.
Kataffa kalimi yakkǝbe kulastǝna.
First, researchers aim to build a whole virus vaccine.
Kulashima auwalbedǝ nyanzǝdǝ kalimi kuli sammabe kǝndowo.
The use of such a virus, be it inactive or dead, aims to elicit a prompt immune response of the human body to a new infection with COVID-19.
Faida kuli anyila kǝndobedǝ shima rowa au roba nyadǝ shima mazar diyi Adam ganabe dǝga kambatǝ COVID-19 bulindǝn katǝ.
A second strategy, subunit vaccines, aims to create a vaccine that sensitises the immune system to certain subunits of the virus.
Kataf kǝn indimidǝ kalimi subunit bedǝye nyadǝ mazar tiyibe dǝga kambatǝ.
In the case of SARS-CoV-2, such research focuses on the S-spike protein that helps the virus intrude the ACE2 enzyme receptor.
Waniye SARS-CoV-2 be kulashidǝ nasha ndǝne tiyibero bana tǝdǝ kuli ACE2 bedǝga kalzǝ rotǝbe.
A third strategy is that of the nucleic acid vaccines (DNA or RNA vaccines, a novel technique for creating a vaccination).
Tartif kǝn yakkǝmidǝ kalimi Nucleic acid be (DNA a RNA began mundǝ kambo kalimiya kǝndobe).
Experimental vaccines from any of these strategies would have to be tested for safety and efficacy.On 16 March 2020, the first clinical trial of a vaccine started with four volunteers in Seattle.
Kalimi shilan jaraftǝbe fasalla smmalan gotǝnadǝ nzǝlifonzǝ a faidanzǝga tawattǝna. Kǝntau March 16 2020 ngal litaribe kǝn auwallega badiyetǝ kǝlanzǝkowu Seattle lan.
The vaccine contains a harmless genetic code copied from the virus that causes the disease.Antibody dependent enhancement has been suggested as a potential challenge for vaccine development for SARS-COV-2, but this is controversial.
Kalimidǝ tiyizǝlan lamba harmless genetic be kuli kasuwa sǝwudinne dǝga gozǝna. Awo tiyi nzǝlifobelan faidatǝdǝ kaziyiya kalimiyedǝga banazǝ kaljiyin nsaha SARS-COV-2 yeladǝn.
There are more than 300 active clinical trials underway as of April 2020.
Jaraf litabe 300 ma kozǝna kǝla laiben da'a loktǝ kǝntau April 2020 ladǝn.
Seven trials were evaluating already approved treatments for malaria, including four studies on hydroxychloroquine or chloroquine.
kurunna kadda jaraftǝnabe kuru tawattǝna kurun Malaria be sǝdinno, kuru surodǝn kulashi Hydroxychloroquine au Chloroquine naso mbeji.
Repurposed antiviral drugs make up most of the Chinese research, with nine phase III trials on remdesivir across several countries due to report by the end of April.
Kurun sha Repurposed antiviral drugs notǝna madǝbe kulashiwo Chinese bega sǝkǝ farmo sana kǝn yakkǝmi, (III) lardǝga kadan jarafsa soro dareram kǝntau April belan hawar kǝladǝn satǝluwo.
A dynamic review of clinical development for COVID-19 vaccine and drug candidates was in place, as of April 2020.Several existing antiviral medications are being evaluated for treatment of COVID-19, including remdesivir, chloroquine and hydroxychloroquine, lopinavir/ritonavir and lopinavir/ritonavir combined with interferon beta.
Nini taganasbega kalimi COVID-19 bega kambatǝro huwuma litabe kurunzǝdǝ April lan furtǝro sǝkinwono. Kurunna kada kǝrmamaro kǝlala COVID-19 faidatinna mbeji kuru jaraftǝ tǝrunaye sǝrodǝn Chloriquine a Hydroxychloroquine a lopinavir a ritonavir a kǝlno interferon betaso mbeji.
There is tentative evidence for efficacy by remdesivir, as of March 2020.
Shaida tawadǝga tǝwandǝna kǝla remdesivir yedǝn kǝntau March 2020 belan.
Clinical improvement was observed in patients treated with compassionate-use remdesivir.
Tawadǝ litabelan tǝwandǝna nasha kamdondiga kurun remdesivir belan gatǝgǝn.
Phase III clinical trials are being conducted in the US, China and Italy.Chloroquine, previously used to treat malaria, was studied in China in February 2020, with preliminary results.
Sana kǝn yakkǝmi kurun dǝga jaraftǝbe lard3 US a China a Italy a lan tǝdǝna. Chloroquine lan faidata kurun Malariabe a kǝndolan kulashi adǝ China lan kǝntau February 2020 jaza badiyarambe tǝwandǝna.
However, there are calls for peer review of the research.
Kuruson botǝga tǝdǝna waltǝ kulashi dǝga nanatǝ kururo.
Korean and Chinese Health Authorities recommend the use of chloroquine.
Huwuma nalewabe Korean a Cinese begaye shawori sadǝna chloroquine lan faidatǝbega.
However, the Wuhan Institute of Virology, while recommending a daily dose of one gram, notes that twice that dose is highly dangerous and could be lethal.
Dasoson yayi huwuma Wuhan be Institute of Virology bedǝbe shawori a kaino watakas wajawoson gram fal lethal ben faidatǝbeg amma inditǝdǝ tajirwa dano.
On 28 March 2020, the FDA issued an emergency use authorisation for hydroxychloroquine and chloroquine at the discretion of physicians treating people with COVID-19.The Chinese 7th edition guidelines also include interferon, ribavirin or umifenovir for use against COVID-19.
Kǝntau March 28 2020 Huwuma FDA wada duwasahibe Hydroxychloroquine a Chloroquine a belan lita be faidatǝ am COVID-19 na gazǝna. Sartǝwa donyi kǝntulurmi Chinese sǝdǝnadǝbe suron interferon a ribavirin a umifenovir a samma faidata COVID-19 gǝrtǝlan.
Preliminary data indicate that high doses of ribavirin are necessary to inhibit SARS-CoV-2 in vitro.
Data saftǝ badiyarambe kǝla adadu ribavirin tǝdǝna dǝye mbuzǝna SARS-CoV-2 sǝro vitrobero zǝkolan.
Nitazoxanide has been recommended for further in vivo study after demonstrating low concentration inhibition of SARS-CoV-2.Studies have demonstrated that initial spike protein priming by transmembrane protease serine 2 (TMPRSS2) is essential for entry of SARS-CoV-2 via interaction with the ACE2 receptor.
Shaworiga tǝna Nitazoxanide faidatǝlan kuruson futǝ faidatǝbe dǝga fuletǝna kǝla SARS-CoV-2 yeladǝn. Kulashidǝbe futǝ fǝlezǝnaladǝn dǝneso kataf transmembrane be dǝlan kǝndon.
The studies of chloroquine and hydroxychloroquine with or without azithromycin have major limitations that have prevented the medical community from embracing these therapies without further study.Oseltamivir does not inhibit SARS-CoV-2 in vitro and has no known role in COVID-19 treatment.
Kulashi kǝla chloroquine a hydroxychloroquine bega sǝrnzǝn azithromycin mbeji au babelan gana tǝdǝna futǝ na litabeso kaltǝyelan kulashi gǝwubaro. Oseltamivir raksǝ SARS-CoV-2 sǝro vitro a COVID-19 kurunjinba.
Cytokine storm can be a complication in the later stages of severe COVID-19.
Cytokine storm bedǝ diwal kaziyi na koji COVID-19 bero waljin.
There is evidence that hydroxychloroquine may have anti-cytokine storm properties.Tocilizumab has been included in treatment guidelines by China's National Health Commission after a small study was completed.
Shaida tǝwandǝnadǝbe fulezǝna hydroxychloroquine waniye tiyinzǝlan anti-cytokine storm mbejiro. Kuru Tocilizumab fasall kurungǝndobedǝro huwuma nalewabe lardǝ China bedǝro sǝkǝna sǝro kulashi ganala sǝdǝnbeladǝn.
It is undergoing a phase 2 non randomised test at the national level in Italy after showing positive results in people with severe disease.
Kǝrmamaro kulashi kǝnindim dǝ kǝlalaiben kuru jilwi yayi kallo gǝnyi gotin jaraftǝ lardǝ Italibe sǝdǝaladǝn fulezǝna am kasuwadǝ na kojiro sǝtana dǝga jazaga nazalan tǝwandǝna.
Combined with a serum ferritin blood test to identify cytokine storms, it is meant to counter such developments, which are thought to be the cause of death in some affected people.
Serum ferritin a bu jaraftǝ turunaladǝn fulezǝna ladǝn cytokine storms, banazǝ am kasuwadǝbe zamǝna lorujin.
The interleukin-6 receptor antagonist was approved by the FDA based on retrospective case studies for treatment of steroid refractory cytokine release syndrome induced by a different cause, CAR T cell therapy, in 2017.
Interleukin-6 huwuma FDA tawattasǝna futǝ kulashi kǝla kurun steroid refractory ye alamaramzǝbe kǝndo a dalilla gade, CAR T cell therapy, sa'a 2017 suwudinso sammalan.
To date, there is no randomised, controlled evidence that tocilizumab is an efficacious treatment for CRS.
Kuro kadeso, ayima kǝkǝllatabe, shaida sǝlǝm kǝmali tocilizumab kaltǝ kurun CRSbe sǝdin tǝwandǝna bawo.
Transferring purified and concentrated antibodies produced by the immune systems of those who have recovered from COVID-19 to people who need them is being investigated as a non-vaccine method of passive immunisation.
Faltǝ sasǝrtǝga nasha kadiyi tiyibe nzǝlifobedǝ bana kunduwu tiyibe am COVID-19 sǝta gazana a am sandilan muradǝnzadǝn kulashi liwula kalimibe gǝnyi ye mundǝ muradǝtǝna.
This strategy was tried for SARS with inconclusive results.
Tartif adǝga jaraftǝ SARS lantǝro jaza kamil gǝnyilan
Viral neutralisation is the anticipated mechanism of action by which passive antibody therapy can mediate defence against SARS-CoV-2.
Kataf dau-dau a gowotǝ mundǝ sha antibody therapy SARS-CoV-2 katǝmatǝga sha gǝrtǝgan.
Other mechanisms however, such as antibody-dependent cellular cytotoxicity and/or phagocytosis, may be possible.
Awo mundǝro faidatǝnasodǝ sandima antibody-dependent cellular a cytotoxicity na adǝgaima phagocytosis, mawo.
Other forms of passive antibody therapy, for example, using manufactured monoclonal antibodies, are in development.
Diwalla gade passive antibody therapy, dǝye misallanzadǝ sandima monoclonal antibodies sanayarambe sǝdandǝnamadǝwo.
Production of convalescent serum, which consists of the liquid portion of the blood from recovered patients and contains antibodies specific to this virus, could be increased for quicker deployment.
Kǝndo convalescent serum bedonyi nashazǝla nji buye kam gazǝnalan kotǝnama dǝga tiyidǝn kuli dǝtǝrayin au tokutokun fafazain.
Coronavirus diseases, a group of closely related syndromes
Kasuwa coronavirus bedǝ kufu kasuwa alamaramza samunbega kǝlta sha sasambu.
Li Wenliang, a doctor at Central Hospital of Wuhan, who later contracted and died of COVID-19 after raising awareness of the spread of the virus.
Lita Li Wenliang, daudi litabe Wuhan, darenzǝ kasuwa COVID-19 sǝda kuru sha loruzǝnadbe kataf kǝla jamabe fatǝbe ga sǝdǝna wande tartǝnyib kǝlan.